Respira Therapeutics, Inc. announced today that the first patient in the United States has been dosed in the multicenter trial of its lead product candidate, RT234-PAH (vardenafil administered as a dry powder inhaled treatment). The VIPAH-PRN 2b trial (Vardenafil Inhaled for Pulmonary Arterial Hypertension – PRN) will consist of two sequential cohorts receiving RT234 as…

eTurboNews artikel hanya untuk pelanggan. Berlangganan adalah KONSULTASI.
Pelanggan masuk di sini Klik di sini untuk berlangganan GRATIS

APA YANG PERLU DIPERHATIKAN DARI PASAL INI:

announced today that the first patient in the United States has been dosed in the multicenter trial of its lead product candidate, RT234-PAH (vardenafil administered as a dry powder inhaled treatment).
The VIPAH-PRN 2b trial (Vardenafil Inhaled for Pulmonary Arterial Hypertension – PRN) will consist of two sequential cohorts receiving RT234 as….
Berlangganan GRATIS.